Key Takeaways
- Canada’s biosimilar market reached $2.4 billion in annual revenues in 2026, growing at 31% year-over-year as provincial switching policies take full effect.
- Biosimilar versions of adalimumab (Humira), ustekinumab (Stelara), and etanercept (Enbrel) now collectively hold over 45% of their respective Canadian market segments.
- Provincial mandatory switching policies have driven average formulary savings of $340 million annually across participating provinces.
- Canadian companies Apobiologix and Pfenex (now Ligand Canada) are active in domestic biosimilar manufacturing partnerships.
Canada’s biosimilar market has entered a period of volume-driven growth unlike anything the domestic pharmaceutical industry has seen in a generation. The combination of patent cliffs hitting the world’s top-selling biologics, aggressive provincial switching policies, and Health Canada’s increasingly efficient biosimilar review process has pushed the Canadian biosimilar market to an estimated $2.4 billion in annual revenues as of mid-2026 up from $840 million just four years ago.
The Patent Cliff Arrives in Canada
The timing of Canada’s biosimilar boom is not coincidental. The Canadian data protection and patent exclusivity framework means that several of the world’s top-grossing biologics lost their last layers of Canadian protection between 2022 and 2026. Adalimumab (Humira), the world’s best-selling drug for most of the past decade, saw its final Canadian compound patent expire in 2023. Ustekinumab (Stelara) followed in 2024, and etanercept (Enbrel) biosimilars have been on Canadian formularies since 2022. Together, these three drugs represented approximately $1.9 billion in pre-biosimilar Canadian annual revenues and the competition from lower-cost alternatives has permanently reshaped their Canadian market dynamics.
| Biosimilar Product | Reference Brand | Canadian Market Share | Top Competing Companies | Annual Formulary Savings (Est.) |
|---|---|---|---|---|
| Multiple adalimumab BSims | Humira | 68% | AbbVie, Amgen, Samsung Bioepis, Organon | ~$145M |
| Ustekinumab BSims | Stelara | 41% | Amgen, Fresenius Kabi, Celltrion | ~$88M |
| Etanercept BSims | Enbrel | 72% | Sandoz, Apobiologix | ~$62M |
| Infliximab BSims | Remicade | 83% | Celltrion, Pfizer, Organon | ~$45M |
| Rituximab BSims | Rituxan | 54% | Sandoz, Pfizer | ~$34M |
Provincial Adoption Rates: The Two-Speed Market
Canada’s federated health system means biosimilar penetration varies dramatically by province. British Columbia and Alberta both of which implemented mandatory switching before 2022 now report biosimilar market shares exceeding 70% in affected drug classes. Ontario’s 2023 mandatory switching program for new patients has driven rapid uptake in the adalimumab and ustekinumab categories, though legacy patients on reference brands were grandfathered in, creating a longer transition tail.
Quebec, historically resistant to mandatory biosimilar switching, introduced a tiered formulary structure in 2025 that makes biosimilars the first-line reimbursed option while allowing exceptions for documented clinical reasons. Early data suggests Quebec’s biosimilar penetration in the adalimumab class has risen from 18% in 2024 to 44% in mid-2026 one of the fastest adoption curves in the country.
Canadian Companies: Apobiologix and the Domestic Manufacturing Question
Most biosimilars sold in Canada are manufactured abroad primarily in South Korea (Samsung Bioepis, Celltrion), the United States (Amgen, Pfizer), and Europe (Sandoz, Fresenius Kabi). Canadian domestic manufacturing capacity in biologics remains limited, though Ottawa’s 2024 Biomanufacturing and Life Sciences Strategy has earmarked $2.2 billion in federal investment to change this over the next decade.
Apobiologix, a Canadian biosimilar company headquartered in Mississauga, focuses on the lower-end biologics and biosimilar formulation segment and has active commercial agreements with several provincial formularies for its etanercept biosimilar program. The company’s ambitions extend to manufacturing partnership for complex monoclonal antibodies, a space it is pursuing with federal biomanufacturing grant support.
The Bottom Line
Canada’s biosimilar market is no longer an emerging story it is a $2.4 billion structural reality that has permanently altered the economics of biologics in this country. For investors, the opportunity now lies in identifying which companies are best positioned to capture share as the next wave of biologic patent cliffs arrives: bevacizumab, trastuzumab, and pertuzumab biosimilars are all expected to see increased Canadian competition before 2028. The provincial policy environment has removed the biggest adoption barrier; price and formulary positioning are now the key competitive levers.